BLUE Stock Overview
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases.
bluebird bio, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.65|
|52 Week High||US$11.70|
|52 Week Low||US$2.87|
|1 Month Change||22.60%|
|3 Month Change||30.99%|
|1 Year Change||-24.33%|
|3 Year Change||-90.99%|
|5 Year Change||-95.30%|
|Change since IPO||-71.57%|
Recent News & Updates
Bluebird, Real Endpoints team up to increase access to pricey gene therapy ZyntegloOct 04
Bluebird bio names interim finance chiefSep 26
bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash WiselyNov 08
Newsflash: bluebird bio, Inc. (NASDAQ:BLUE) Analysts Have Been Trimming Their Revenue ForecastsAug 11
What You Need To Know About The bluebird bio, Inc. (NASDAQ:BLUE) Analyst Downgrade TodayJul 22
We Think bluebird bio (NASDAQ:BLUE) Can Afford To Drive Business GrowthJul 21
Industry Analysts Just Upgraded Their bluebird bio, Inc. (NASDAQ:BLUE) Revenue Forecasts By 2.7%Apr 21
Analysts Have Just Cut Their bluebird bio, Inc. (NASDAQ:BLUE) Revenue Estimates By 15%Feb 17
|BLUE||US Biotechs||US Market|
Return vs Industry: BLUE underperformed the US Biotechs industry which returned -16.1% over the past year.
Return vs Market: BLUE underperformed the US Market which returned -20.5% over the past year.
|BLUE Average Weekly Movement||14.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: BLUE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: BLUE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
bluebird bio, Inc. Fundamentals Summary
|BLUE fundamental statistics|
Is BLUE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLUE income statement (TTM)|
|Cost of Revenue||US$283.98m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-5.20|
|Net Profit Margin||-8,387.88%|
How did BLUE perform over the long term?See historical performance and comparison